Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biodetection

    BioFire Receives FDA Clearance for the FilmArray 2.0

    By Global Biodefense StaffFebruary 26, 2015
    BioWatch Trigger Detector
    Share
    Facebook LinkedIn Reddit Email

    BioFire Diagnostics, LLC today announced that it has received FDA clearance and CE-IVD marking of the FilmArray 2.0 system. The system is expected to be commercially available by the end of March 2015.

    Since its acquisition by bioMérieux, BioFire Diagnostics has reported more than 60% organic growth in sales at the end of 2014.

    FilmArray 2.0 features higher throughput, allowing customers random access processing up to 175 samples in a day within a small footprint. The system offers the same strengths of rapidity, ease-of-use, integration and accuracy that characterize the current FilmArray. Each system accommodates 1 to 8 FilmArray 2.0 units operated by a single computer. The system is also capable of connecting to Laboratory Information Systems.

    “As we develop additional applications for the FilmArray system, it is essential that customers are able to accommodate high throughput with as small of a footprint as possible,” said Randy Rasmussen, bioMérieux Corporate Vice President of Molecular Biology and CEO of BioFire Diagnostics. “We look forward to introducing the FilmArray 2.0 system to clinical laboratories throughout the world and are excited for the expected benefits FilmArray’s syndromic approach will have on the fight against infectious diseases, antibiotic stewardship and more broadly on patient care and healthcare cost reduction.”

    Currently, the FilmArray menu includes three FDA-cleared and CE-marked panels: the Respiratory Panel, the Blood Culture Identification Panel and the Gastrointestinal Panel.

    Additionally, BioFire has initiated studies for its Meningitis-Encephalitis Panel, with FDA submission expected this year.

    Bioterrorism BioWatch
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleiBio Adds Anthrax Antibodies to Product Pipeline
    Next Article Biodefense Headlines – Mar 1, 2015

    Related Stories

    First Light Diagnostics Receives FDA Clearance for Rapid Anthrax Test

    December 5, 2023

    Chlorine Exposure Biomarkers in a Large Animal Model

    December 5, 2023

    Inflammatix Completes Development for Acute Infection and Sepsis Test System

    November 15, 2023

    NanoViricides’ Phase 1 Broad-Spectrum Antiviral Highly Effective for Mpox and Smallpox

    November 14, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Dec 6
    Virtual Event Virtual Event
    6:00 am - 7:00 am EST

    AMR One Health Priority Research Agenda: Transmission

    Mar 12
    Virtual Event Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.